Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)

被引：0
|
作者：
Bello Roufai, D.
Goncalves, A.
de la Motte Rouge, T.
Akla, S.
Blonz, C.
Grenier, J.
Gligorov, J.
Saghatchian, M.
Bailleux, C.
Simon, H.
Desmoulins, I.
Tharin, Z.
Renaud, E.
Bertho, M.
Benderra, M-a
Delaloge, S.
Robert, L.
Cottu, P.
Pierga, J. Y.
Loirat, D.
Bertucci, A.
Renouf, B.
Bidard, F. C.
Lerebours, F.
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Institut Paoli Calmettes,Aix
[3] CRCM,Marseille Univ, CNRS, INSERM, Department of Medical Oncology
[4] Centre Eugène Marquis,Department of Medical Oncology
[5] Gustave Roussy,Department of Cancer Medicine
[6] Institut de Cancérologie de l’Ouest,Department of Medical Oncology
[7] Institut du Cancer d’Avignon,Department of Medical Oncology
[8] Hôpital Tenon,Department of Medical Oncology
[9] AP-HP,Breast Cancer Unit
[10] American Hospital of Paris,Department of Medical Oncology
[11] Centre Antoine Lacassagne,Department of Medical Oncology
[12] University Hospital of Brest,Department of Medical Oncology
[13] Centre Georges-François Leclerc,INSERM U938, Institut Universitaire de Cancérologie
[14] UVSQ,undefined
[15] Paris-Saclay University,undefined
[16] Paris Cité University,undefined
[17] AP-HP Sorbonne Université,undefined
来源：
ONCOGENE | 2023年 / 42卷 / 17期
关键词：
D O I：
10.1038/s41388-023-02615-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1417 / 1417
页数：1
相关论文
共 50 条
  • [31] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
    Sarah E. Burnette
    Emily Poehlein
    Hui-Jie Lee
    Jeremy Force
    Kelly Westbrook
    Heather N. Moore
    Breast Cancer Research and Treatment, 2023, 197 : 369 - 376
  • [32] Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Llombart-Cussac, Antonio
    Sledge, George
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Andre, Valerie
    Bian, Yuanyuan
    Shahir, Ashwin
    van Hal, Gertjan
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
    Maria Ciruelos, Eva
    Rugo, Hope S.
    Mayer, Ingrid A.
    Levy, Christelle
    Forget, Frederic
    Delgado Mingorance, Juan Ignacio
    Safra, Tamar
    Masuda, Norikazu
    Park, Yeon Hee
    Juric, Dejan
    Conte, Pierfranco
    Campone, Mario
    Loibl, Sibylle
    Iwata, Hiroji
    Zhou, Xiaolei
    Park, Jinhee
    Ridolfi, Antonia
    Lorenzo, Ines
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 2005 - +
  • [34] Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
    Juric, Dejan
    Janku, Filip
    Rodon, Jordi
    Burris, Howard A.
    Mayer, Ingrid A.
    Schuler, Martin
    Seggewiss-Bernhardt, Ruth
    Gil-Martin, Marta
    Middleton, Mark R.
    Baselga, Jose
    Bootle, Douglas
    Demanse, David
    Blumenstein, Lars
    Schumacher, Karl
    Huang, Alan
    Quadt, Cornelia
    Rugo, Hope S.
    JAMA ONCOLOGY, 2019, 5 (02)
  • [35] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [36] Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
    Welt, Anja
    Wiesweg, Marcel
    Theurer, Sarah
    Abenhardt, Wolfgang
    Groschek, Matthias
    Mueller, Lothar
    Schroeder, Jan
    Tewes, Mitra
    Chiabudini, Marco
    Potthoff, Karin
    Bankfalvi, Agnes
    Marschner, Norbert
    Schuler, Martin
    Breitenbuecher, Frank
    CANCER MEDICINE, 2020, 9 (13): : 4527 - 4539
  • [37] Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer
    Turner, Stuart
    Chia, Stephen
    Kanakamedala, Hemanth
    Hsu, Wei-Chun
    Park, Jinhee
    Chandiwana, David
    Ridolfi, Antonia
    Yu, Chu-Ling
    Zarate, Juan Pablo
    Rugo, Hope S.
    ONCOLOGIST, 2021, 26 (07): : E1133 - E1142
  • [38] A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
    Jhaveri, Komal
    Drago, Joshua Z.
    Shah, Payal Deepak
    Wang, Rui
    Pareja, Fresia
    Ratzon, Fanni
    Iasonos, Alexia
    Patil, Sujata
    Rosen, Neal
    Fornier, Monica N.
    Sklarin, Nancy T.
    Chandarlapaty, Sarat
    Modi, Shanu
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3867 - 3875
  • [39] Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
    Jhaveri, Komal L.
    Accordino, Melissa K.
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Schmid, Peter
    Saura, Cristina
    Turner, Nicholas C.
    Varga, Andrea
    Cheeti, Sravanthi
    Hilz, Stephanie
    Hutchinson, Katherine E.
    Jin, Yanling
    Royer-Joo, Stephanie
    Peters, Ubong
    Shankar, Noopur
    Schutzman, Jennifer L.
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)
  • [40] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
12345